Orna Therapeutics

aid: orna-therapeutics
name: Orna Therapeutics
description: 'Orna Therapeutics is a Cambridge, Massachusetts biotechnology company, founded in 2019 on research from MIT
  and built by MPM Capital, that engineers circular RNA (oRNA) paired with lipid nanoparticle delivery so a patient''s own
  body generates cell therapies — its lead program ORN-252 is a CD19-targeting in vivo CAR-T designed for B-cell-driven autoimmune
  disease. Orna acquired ReNAgade Therapeutics in 2024, combining its circular RNA platform with ReNAgade''s LNP delivery
  and RNA editing capabilities, and Eli Lilly announced a definitive agreement to acquire Orna on 2026-02-09 for up to $2.4B.
  Orna is a therapeutics developer, not a software vendor: it publishes no API, developer portal, SDK or machine-readable
  contract, and as of this profile its own domain ornatx.com redirects in whole to Eli Lilly''s subsidiaries page.'
url: https://raw.githubusercontent.com/api-evangelist/orna-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  - url: https://www.ornatx.com/
    status: 301
    note: declared website redirects to https://www.lilly.com/science/subsidiaries — a different registrable domain (ornatx.com
      -> lilly.com), possible rename or acquisition (probed 2026-09-03, roadmap#169)
  generated: '2026-09-02'
  method: derived
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-10-06'
tags:
- Company
- Biotechnology
- Therapeutics
- RNA
- Life Sciences
- Pharmaceuticals
- Cell Therapy
- Research
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- url: https://www.lilly.com/news
  type: Blog
- type: DomainSecurity
  url: security/orna-therapeutics-domain-security.yml
- type: Website
  url: https://www.ornatx.com/
- type: GitHubOrganization
  url: https://github.com/OrnaComputationTeam
- type: ParentCompany
  url: https://www.lilly.com/science/subsidiaries
- type: LinkedIn
  url: https://www.linkedin.com/company/ornatx
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: defunct
  detail: Orna Therapeutics is a clinical-stage RNA therapeutics developer with no software product, and since Eli Lilly's
    acquisition (definitive agreement announced 2026-02-09) its entire domain ornatx.com answers HTTP 301 to https://lilly.com/science/subsidiaries
    — every /.well-known/* path included — so the only surface it still operates is a GitHub org of 44 forked third-party
    RNA structure-prediction tools and one internal CodeCommit sync action, none of which is an API.
  evidence:
  - url: https://www.ornatx.com/
    status: 301
  - url: https://www.ornatx.com/.well-known/api-catalog
    status: 301
  - url: https://www.ornatx.com/openapi.json
    status: 404
  - url: https://www.ornatx.com/llms.txt
    status: 404
  - url: https://github.com/OrnaComputationTeam
    status: 200
  checked: '2026-08-26'